Mesoblast share price dips amid latest class action news

The company is being taken to court by another unhappy shareholder.

| More on:
An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Mesoblast share price is in the red on Thursday, slipping 1.93% to trade at $1.01
  • The dip comes amid news the company has been hit with another class action
  • Mesoblast has vowed to fight the latest allegations and noted it recently settled a similar suit in the US without admitting liability

The Mesoblast Limited (ASX: MSB) share price is slipping lower as the company is hit with another class-action lawsuit.

A shareholder is suing the biotechnology company alleging it misled the market about its remestemcel-L product.

At the time of writing, the Mesoblast share price is $1.01, 1.93% lower than its previous close.

For context, the S&P/ASX All Ordinaries Index (ASX: XAO) is currently also down 1.41%. Meanwhile, the S&P/ASX 200 Health Care Index (ASX: XHJ) is up 0.26%.

Let's take a closer look at the details.

Mesoblast facing a new class action

The Mesoblast share price is slipping amid news a class action proceeding in the Federal Court of Australia has been served on the company.

Law firm William Roberts Lawyers has brought the action against Mesoblast. The firm is representing a person who bought shares in the company between February 2018 and December 2020.

It alleges the company engaged in unlawful conduct that misled the market about remestemcel-L. 

"Mesoblast will vigorously defend against the proceeding," the company said in a statement published to the ASX.

It also noted it resolved a similar suit in the United States for $2 million without admitting liability in April. The company's insurer covered the cost of the settlement.

Mesoblast has reportedly faced multiple class actions in the US on similar allegations.

Previous actions claimed Mesoblast didn't inform investors about adverse aspects of particular remestemcel-L trials, the Australian Financial Review reported in 2020.

That reportedly prompted the FDA to demand a further controlled study of the drug before it could be given the green light to treat acute graft versus host disease in children.

And it might not be the last time the market hears news of a class action against the company.

Australian law firm Phi Finney McDonald has also been looking into a class action against Mesoblast over the past few months.

Mesoblast share price snapshot

This year has been rough on the Mesoblast share price.

The stock has tumbled nearly 28% year to date. It's also nearly 45% lower than it was this time last year.

Should you invest $1,000 in Macquarie Group Limited right now?

Before you buy Macquarie Group Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Macquarie Group Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Healthcare Shares

Guess which ASX 200 stock is jumping 16% on big news

Let's find out what news is getting investors excited this afternoon.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

What did CSL have to say at Macquarie's 2025 conference?

Does this business have a healthy growth outlook?

Read more »

smiling health care workers in a medical setting
Healthcare Shares

Sonic Healthcare shares are down more than 40% since 2021. Will its AI initiative be the catalyst for a turnaround?

Could AI spark a recovery for this ASX healthcare stock?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »